Alkermes/$ALKS

13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX

About Alkermes

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Ticker

$ALKS
Primary listing

Industry

Biotechnology

Headquarters

Dublin, Ireland

Employees

1,800

ISIN

IE00B56GVS15

Alkermes Metrics

BasicAdvanced
$4.8B
13.79
$2.09
0.35
-

What the Analysts think about Alkermes

Analyst ratings (Buy, Hold, Sell) for Alkermes stock.

Bulls say / Bears say

Alkermes' stock has surged by 47.72% over the past three months, indicating strong market confidence in the company's performance. (gurufocus.com)
The company has initiated a Phase 2 study of ALKS 2680 for the treatment of idiopathic hypersomnia, expanding its pipeline in the sleep disorder market. (wikipedia.org)
Analysts have set an average 12-month price target of $38.33 for Alkermes, suggesting a potential upside of approximately 26% from the current price. (marketbeat.com)
Alkermes' revenue has declined by 12.31% year-over-year, raising concerns about the company's growth trajectory. (forbes.com)
The company's EBITDA has decreased by 21.34% year-over-year, indicating potential challenges in maintaining profitability. (forbes.com)
Alkermes' net income has decreased by 84.7% over the last two quarters, with an average decrease of 28.7% per quarter, highlighting significant financial challenges. (indmoney.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.

Alkermes Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Alkermes Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ALKS

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs